Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...
Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring
Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...
Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review
Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...
Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year
Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...
AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance
AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...
WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....
Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing
Alphamab Oncology (HKG: 9966) announced that it has entered into a licensing agreement with Pathos...
Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing
In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round...
CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma
CARsgen Therapeutics (HKG: 2171) announced that CT0596 has received clinical approval from the National Medical...
InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma
InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...
Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC
Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...
Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma
Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA)...
FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States
On July 29, 2026, the U.S. FDA granted a biologics license to Ezplaz Freeze Dried...
Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer
Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...
HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months...
Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership
Siemens Healthineers AG (ETR: SHL) and Cleveland Clinic announced the signing of a 10-year strategic...
Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership
Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) announced that it has signed a Strategic Cooperation Framework...
Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits
Sansure Biotech Inc. (SHA: 688289) announced that five of its nucleic acid diagnostic kits have...
Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s TQB2102,...
Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd. announced that FL115 subcutaneous injection (administered once every three weeks)...